Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity.
作者信息
Zhang Dianying, Zhao Jingjing, Zhang Yujing, Jiang Hongfei, Liu Dan
机构信息
Medical Education Department, Guangdong Provincial People's Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, China.
Sleep Medicine Center, Huai'an No.3 People's Hospital, Huai'an, China.
出版信息
Front Immunol. 2024 Dec 10;15:1490129. doi: 10.3389/fimmu.2024.1490129. eCollection 2024.
Abstract
摘要
相似文献
1
Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity.重新审视免疫检查点抑制剂：提高疗效和降低毒性的新策略。
Front Immunol. 2024 Dec 10;15:1490129. doi: 10.3389/fimmu.2024.1490129. eCollection 2024.
2
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.免疫检查点抑制剂的免疫相关不良反应显著预测了晚期非小细胞肺癌患者的持久疗效，即使是在应答者中也是如此。
Oncologist. 2020 Apr;25(4):e679-e683. doi: 10.1634/theoncologist.2019-0299. Epub 2019 Nov 19.
3
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.美国 FDA 批准的免疫检查点抑制剂的毒性负担模式。
J Exp Clin Cancer Res. 2023 Jan 5;42(1):4. doi: 10.1186/s13046-022-02568-y.
4
Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.免疫检查点抑制剂引起的免疫相关不良反应中的自身免疫：重点关注自身免疫性皮肤毒性和肺炎。
Immunol Rev. 2023 Sep;318(1):37-50. doi: 10.1111/imr.13258. Epub 2023 Aug 7.
5
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.免疫相关不良反应与癌症患者免疫检查点抑制剂疗效的相关性：系统评价和荟萃分析。
BMC Med. 2020 Apr 20;18(1):87. doi: 10.1186/s12916-020-01549-2.
6
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.免疫检查点抑制剂引发的迟发性和持久性免疫相关不良事件：免疫治疗中一个被忽视的方面。
Eur J Cancer. 2021 May;149:153-164. doi: 10.1016/j.ejca.2021.03.010. Epub 2021 Apr 14.
7
The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC.免疫检查点抑制剂在老年非小细胞肺癌患者中的毒性与疗效的相关性。
Immunotherapy. 2024;16(16-17):1057-1068. doi: 10.1080/1750743X.2024.2394382. Epub 2024 Sep 13.
8
Traditional Chinese medicine enhances the effectiveness of immune checkpoint inhibitors in tumor treatment: A mechanism discussion.中药增强免疫检查点抑制剂在肿瘤治疗中的疗效：机制探讨
J Ethnopharmacol. 2025 Feb 10;338(Pt 1):118955. doi: 10.1016/j.jep.2024.118955. Epub 2024 Oct 18.
9
Advances on immune-related adverse events associated with immune checkpoint inhibitors.免疫检查点抑制剂相关免疫相关不良事件的研究进展
Front Med. 2021 Feb;15(1):33-42. doi: 10.1007/s11684-019-0735-3. Epub 2020 Aug 10.
10
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.免疫检查点抑制剂免疫相关不良事件的临床特征与治疗
Immune Netw. 2020 Feb 17;20(1):e9. doi: 10.4110/in.2020.20.e9. eCollection 2020 Feb.
引用本文的文献
1
Exploring the predictive "psycho-biomarkers" for checkpoint immunotherapy in cancer.探索癌症检查点免疫疗法的预测性“心理生物标志物”。
Front Immunol. 2025 Jul 21;16:1590670. doi: 10.3389/fimmu.2025.1590670. eCollection 2025.
2
Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database.卡铂在非小细胞肺癌中的真实世界安全性：基于FAERS数据库的回顾性信号检测和亚组分析
Front Med (Lausanne). 2025 Jun 16;12:1590738. doi: 10.3389/fmed.2025.1590738. eCollection 2025.
3
Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach.肺癌免疫治疗中的耐药性及如何克服它：遗传学视角与联合治疗方法的见解
Cells. 2025 Apr 12;14(8):587. doi: 10.3390/cells14080587.
4
Combining immune checkpoints with TNFSF agonists: a new horizon for cancer and autoimmune therapies.将免疫检查点与肿瘤坏死因子超家族（TNFSF）激动剂相结合：癌症与自身免疫性疾病治疗的新前景。
Front Immunol. 2025 Mar 17;16:1557176. doi: 10.3389/fimmu.2025.1557176. eCollection 2025.
5
Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations.揭示癌症干细胞治疗的未来：对新兴创新的叙事性探索。
Discov Oncol. 2025 Mar 22;16(1):373. doi: 10.1007/s12672-025-02102-4.
6
Immune Checkpoint Blockade Combined with AbnobaViscum Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence.免疫检查点阻断联合鸦胆子油治疗与晚期或转移性非小细胞肺癌患者生存率提高相关：一项符合欧洲肿瘤内科学会报告真实世界证据指南的登记研究。
Pharmaceuticals (Basel). 2024 Dec 18;17(12):1713. doi: 10.3390/ph17121713.
本文引用的文献
1
Cost effectiveness of immune checkpoint inhibitors for treatment of Hepatocellular Carcinoma: A systematic review and Meta-analysis.免疫检查点抑制剂治疗肝细胞癌的成本效益：一项系统评价和Meta分析。
Surg Oncol. 2023 Oct 24;51:102013. doi: 10.1016/j.suronc.2023.102013.
2
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.BRAF V600E 突变且错配修复缺陷或微卫星不稳定高转移性结直肠癌患者在免疫检查点抑制剂后使用 BRAF+EGFR+/-MEK 抑制剂。
Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290. Epub 2024 Aug 22.
3
Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance.小分子抑制剂作为癌症免疫治疗的佐剂：增强疗效和克服耐药性。
Front Immunol. 2024 Aug 5;15:1444452. doi: 10.3389/fimmu.2024.1444452. eCollection 2024.
4
Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment.用于癌症治疗的刺激响应性小分子前药的开发策略。
Front Pharmacol. 2024 Jul 31;15:1434137. doi: 10.3389/fphar.2024.1434137. eCollection 2024.
5
Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors.客观缓解率是免疫检查点抑制剂治疗转移性尿路上皮癌患者长期总生存期的替代标志物。
Clin Genitourin Cancer. 2024 Oct;22(5):102163. doi: 10.1016/j.clgc.2024.102163. Epub 2024 Jul 20.
6
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.非小细胞肺癌患者中 PD-L1 表达和肿瘤突变负担的个体内变异及其对免疫检查点抑制剂治疗结局的影响。
Ann Oncol. 2024 Oct;35(10):902-913. doi: 10.1016/j.annonc.2024.06.014. Epub 2024 Jun 29.
7
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.皮质类固醇和其他免疫抑制剂治疗黑色素瘤相关免疫不良反应和检查点抑制剂疗效。
Eur J Cancer. 2024 Aug;207:114172. doi: 10.1016/j.ejca.2024.114172. Epub 2024 Jun 15.
8
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.监测免疫检查点抑制后免疫失调（MEDALLION）：一项观察性癌症免疫治疗队列研究的方案。
BMC Cancer. 2024 Jun 14;24(1):733. doi: 10.1186/s12885-024-12468-3.
9
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers.免疫检查点抑制剂治疗早期错配修复缺陷/微卫星高度不稳定胃肠道肿瘤后的非手术治疗。
Cancer Treat Rev. 2024 Jul;128:102752. doi: 10.1016/j.ctrv.2024.102752. Epub 2024 May 12.
10
Follow-up biopsies in gastrointestinal immune checkpoint inhibitor toxicity may show markedly different inflammatory patterns than initial injury.胃肠道免疫检查点抑制剂毒性的随访活检可能显示与初始损伤明显不同的炎症模式。
Hum Pathol. 2024 Jun;148:60-65. doi: 10.1016/j.humpath.2024.05.001. Epub 2024 May 10.
Zotero 插件